Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. [electronic resource]
Producer: 20110728Description: 2259-65 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- therapeutic use
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Disease-Free Survival
- Endometrial Neoplasms -- drug therapy
- Female
- Humans
- Kaplan-Meier Estimate
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Salvage Therapy -- methods
- Vascular Endothelial Growth Factor A -- biosynthesis
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.